-
Astellas announces EC approval of Xtandi for expanded prostate cancer use
25 Apr 2024 11:38 GMT
… for castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer, the first … parts of the body (metastases) and the disease still … who have undergone definitive prostate cancer treatment will experience BCR … high risk for metastasis.
-
Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up.
25 Apr 2024 07:49 GMT
… primary curative radiation therapy for prostate cancer (PCa), as prospective studies with … (95% CI, 82 to 100), metastasis-free survival was 82% (95% …
-
EC grants label extension approval for Astellas' Xtandi for use in additional recurrent early prostate cancer treatment setting
25 Apr 2024 06:20 GMT
… -metastatic hormone-sensitive prostate cancer at high risk of metastasizing, which could become … -sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer …
-
European Commission approves Astellas’ drug for expanded prostate cancer Treatment
24 Apr 2024 14:24 GMT
… 9% reduction in risk.”
Prostate cancer can lead to metastasis
Dr Antonio Alcaraz … for advanced prostate cancer.
“Many men with hormone-sensitive prostate cancer undergo arduous … -sensitive prostate cancer (nmCSPC) with BCR at high risk for metastasis in …
-
EC approves Astellas’ Xtandi for high-risk prostate cancer treatment
24 Apr 2024 11:23 GMT
… (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are not suitable … the early, recurrent hormone-sensitive prostate cancer setting. Astellas is in active … castration-sensitive prostate cancer with BCR at high risk for metastasis.
Last month …
-
A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia.
24 Apr 2024 08:24 GMT
… castrate-resistant prostate cancer at high risk of developing overt metastases but with … prostrate cancer have demonstrated increased metastasis-free survival and overall survival …
-
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
24 Apr 2024 02:54 GMT
… -metastatic hormone-sensitive prostate cancer at high risk of metastasizing, which could become … -sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer …
-
European Commission Approves Astellas' Xtandi For Recurrent Early Prostate Cancer Treatment
24 Apr 2024 01:15 GMT
… recurrent non-metastatic hormone-sensitive prostate cancer who are unsuitable for … recurrent non-metastatic hormone-sensitive prostate cancer in the European Union.
… -sensitive prostate cancer with biochemical recurrent at high risk for metastasis in …
-
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
22 Apr 2024 12:47 GMT
… Surveillance (AS) for prostate cancer, the Decipher Prostate … advance scientific understanding of prostate cancer. Specifically, the researchers … -transcriptome data for prostate cancer samples to gain … risk of developing metastasis with standard treatment. …
-
New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
22 Apr 2024 12:44 GMT
… Surveillance (AS) for prostate cancer, the Decipher Prostate … advance scientific understanding of prostate cancer. Specifically, the researchers … -transcriptome data for prostate cancer samples to gain … risk of developing metastasis with standard treatment. …